Affiliation:
1. City Hospital No. 40 of the Kurortny District
Abstract
Objective: to analyze the long-term oncological results of surgical treatment of patients with stage cT1-сТ2аN0M0 renal cell cancer.Materials and methods. The analysis included 326 patients who underwent partial nephrectomy (PN) in 210 (64.42 %) and radical nephrectomy (RN) - in 116 (35.58 %). Stage cT1a tumors were found in 129 (39.57 %), cT1b - in 149 (45.71 %), cT2a - in 48 (14.72 %) cases. PN and RN for cT1a was performed in 113 (53.81 %) and 16 (13.79 %), for cT1b -in 86 (40.95 %) and 63 (54.31 %), for cT2a - in 11 (5.24 %) and 37 (31.90 %) patients. We used open approach in 5 (1.53 %), laparoscopic in 148 (45.26 %) and robotic in 173 (53.21 %). The median follow-up was 49.9 [26.0; 81.4] months.Results. In the group of patients with stage cT1a disease, 4 recurrences of the tumor process were revealed (3 local recurrences after PN and 1 after RN). Seven deaths were recorded (4 after PR and 3 after RN). Two deaths occurred due to the progression of kidney cancer (1 after PN and 1 after RN). 5-year disease-free survival after PN and RN was 95.93 ± 2.32 % versus 92.31 ± 7.39 % (p >0.05); 5-year overall survival - 96.48 ± 2.08 % versus 85.56 ± 9.65 % (p >0.05); 5-year cancer-specific survival - 98.33 ± 1.65 % versus 92.25 ± 6.5 % (p >0.05).In the group of patients with stage cT1b disease, 12 recurrences were revealed (5 after PN and 7 after RN). 14 deaths were recorded (4 after PN and 10 after RN). Four deaths were related to the development of kidney cancer (all after RN). 5-year disease-free survival after PN and RN was 92.97 ± 3.1 % versus 86.99 ± 4.64 % (p >0.05); 5-year overall survival -95.1 ± 2.78 % versus 88.63 ± 4.4 % (p >0.05); 5-year cancer-specific survival - 100 % versus 94.1 ± 3.33 % (p >0,05).There were no recurrences of the oncological process or deaths after PN in the group of patients with the stage of cT2a disease during four years of follow-up. After RN six recurrences of the oncological process, four deaths (3 of them due to the progression of kidney cancer) were recorded. Thus, the disease-free survival at was 80.57 ± 7.15 %; overall survival - 90.28 ± 5.34 %; cancer-specific survival - 93.63 ± 4.37 %.Conclusion. PN is the priority treatment for renal cell cancer. Oncological results of nephron-sparing surgery are superior to the results of RN, however, these differences are not reliable and require a longer study.
Publisher
Publishing House ABV Press
Subject
Urology,Nephrology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery
Reference16 articles.
1. Axel E.M., Matveev V.B. Statistics of malignant tumors of urinary and male urogenital organs in Russia and the countries of the former USSR. Onkourologiya = Cancer Urology 2019;15(2):15-24. (In Russ.). DOI: 10.17650/1726-9776-2019-15-2-15-24.
2. State of oncological care in Russia in 2017. Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2018. 236 p. (In Russ.).
3. Ljungberg B., Bensalah K., Canfield S. et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67(5):913-24. DOI: 10.1016/j.eururo.2015.01.005.
4. Campbell S., Uzzo R.G., Allaf M.E. et al. Renal mass and localized renal cancer: AUA guideline. J Urol 2017;198:520-9. DOI: 10.1016/j.juro.2017.04.100.
5. Kim S.P., Campbell S.C., Gill I. et al. Collaborative review of risk benefit trade offs between partial and radical nephrectomy in the management of anatomically complex renal masses. Eur Urol 2017;72(1):64-75. DOI: 10.1016/j.eururo.2016.11.038.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献